查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1566812

心臟病診斷市場：按類型、最終用戶分類：2024-2033 年全球機會分析與產業預測

Heart Attack Diagnostics Market By Type (Electrocardiogram, Blood Tests, Angiogram, Computerized Cardiac Tomography, Others), By End User (Hospitals, Diagnostics Centers, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 260 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

心臟病診斷市場

2023 年心臟病診斷市場價值為 92 億美元，預計 2024 年至 2033 年複合年成長率為 8.6%，到 ​​2033 年達到 211 億美元。

心臟病發作診斷包括診斷患者的血壓、體溫和脈搏率。將進行一系列評估以確定您是否經歷過心臟病發作，也稱為心肌梗塞。一系列診斷測試包括測量心臟電活動的心電圖 (EKG) 和檢測心肌酵素（例如肌鈣蛋白）的血液測試，心肌酵素在心肌受損時會釋放到血液中，其中包括成像測試等。冠動脈攝影術和超音波心動圖的可視化。

久坐生活方式的增加導致文明病急劇增加，包括心臟病發作。因此，心臟病診斷的需求激增，加速了市場的成長。此外，全球老年人口的快速成長正在為市場擴張鋪平道路。將人工智慧引入心電圖測試可能會成為未來的主流，因為這將縮短診斷時間。台灣一家醫院進行AI與心電圖同化研究，將診斷時間縮短10分鐘。人工智慧的不斷改進正在提高臨床決策支援系統的有效性，並鼓勵醫療保健專業人員採用這項技術。

然而，這些診斷測試非常昂貴，導致最終用戶無法利用其優勢並抑制市場開拓。此外，引進新診斷技術還存在各種監管障礙，這為市場擴張帶來了挑戰。包括美國食品藥物管理局、歐洲藥品管理局、日本藥品和醫療設備管理局以及印度中央藥品標準控制組織在內的各個監管機構都要求新診斷技術遵守各自的監管指南才能進入市場。相反，將創新技術引入市場表明其前景光明。例如，德國醫療公司西門子醫療公司推出了一款手持設備，聲稱可以在 30 分鐘內檢測出心臟病發作。希望此類設備的推出將加快治療速度並增加患者康復的機會。

按部門審查

心臟病診斷市場分為類型、最終用戶和地區。依類型分類，市場分為心電圖、血液檢查、血管造影術、電腦心臟斷層掃描等。依最終用戶分類，可分為醫院、診斷中心等。從區域來看，分析涵蓋北美、歐洲、亞太地區和拉丁美洲/中東/非洲。

該報告可以客製化。

  • 根據客戶興趣加入公司簡介
  • 擴大公司簡介列表
  • 歷史市場資料

目錄

第1章簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 關鍵投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章心臟病診斷市場：按類型

  • 市場概況
  • 心電圖
  • 驗血
  • 血管造影術
  • 電腦心臟斷層掃描
  • 其他

第5章心臟病診斷市場：依最終用戶分類

  • 市場概況
  • 醫院
  • 診斷中心
  • 其他

第6章心臟病診斷市場：按地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國心臟病診斷市場
    • 加拿大心臟病診斷市場
    • 墨西哥心臟病診斷市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 法國心臟病診斷市場
    • 德國心臟病診斷市場
    • 義大利心臟病診斷市場
    • 西班牙心臟病診斷市場
    • 英國心臟病診斷市場
    • 其他歐洲心臟病診斷市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 中國心臟病診斷市場
    • 日本心臟病診斷市場
    • 印度心臟病診斷市場
    • 韓國心臟病診斷市場
    • 澳洲心臟病診斷市場
    • 其他亞太心臟病診斷市場
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 巴西心臟病診斷市場
    • 南非心臟病診斷市場
    • 沙烏地阿拉伯心臟病診斷市場
    • 其他拉丁美洲/中東/非洲心臟病診斷市場

第7章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2023年）

第8章 公司簡介

  • Bionet Co., Ltd
  • TOSHIBA CORPORATION
  • Bio-Rad Laboratories Inc
  • Life Sign LLC
  • Schiller AG
  • Beckman Coulter, Inc.
  • GE Healthcare
  • Hitachi Medical Systems
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
簡介目錄
Product Code: A12689

Heart Attack Diagnostics Market

The heart attack diagnostics market was valued at $9.2 billion in 2023 and is projected to reach $21.1 billion by 2033, growing at a CAGR of 8.6% from 2024 to 2033.

Heart attack diagnostic comprises of diagnosing the blood pressure, temperature, and pulse rate of a patient. A series of evaluations are conducted to determine if an individual has experienced a heart attack, also known as myocardial infarction. The series of diagnostic tests includes an electrocardiogram (EKG) which measures the electrical activity of heart, blood tests to detect cardiac enzymes such as troponin which are released into the bloodstream in case of heart muscle damage, and imaging tests such as coronary angiography or echocardiography for the visualization of heart & its blood vessels.

Increase in sedentary lifestyles has led to surge in occurrence of lifestyle diseases, including heart attack. This has led to surge in demand for heart attack diagnostics, hence augmenting the growth of the market. Furthermore, exponential growth in the geriatric population globally is opening avenues for the expansion of the market. The assimilation of AI in the EKG testing is poised to become mainstream in the future as it reduces the diagnosis time. A hospital in Taiwan conducted research regarding the assimilation of AI and EKG, which reduced the diagnosis period by 10 minutes. Constant improvements in AI are enhancing the efficacy of clinical decision support system, encouraging medical practitioners to adopt the technology.

However, these diagnostics tests are extremely expensive and prevent several end users from leveraging their benefits, hence restraining the market development. In addition, the introduction of new diagnostic technologies is subject to various regulatory hurdles, hence presenting challenges for the expansion of the market. Different regulatory bodies such as the U.S. Food and Drug Administration, European Medicines Agency, the Pharmaceuticals and Medical Devices Agency in Japan, and Central Drugs Standard Control Organization in India have mandated the adherence to their respective regulatory guidelines for the entry of new diagnostic technologies into the market. Contrarily, innovative techniques being introduced into the market are an indicator of its promising future. For instance, Siemens Healthineers, a German healthcare company, has introduced a handheld device which claims to detect heart attack in less than 30 minutes. The launch of such devices is expected to quicken treatment delivery and increase the chances of recovery for patients in the future.

Segment Review

The heart attack diagnostics market is segmented into type, end user, and region. On the basis of type, the market is divided into electrocardiogram, blood tests, angiogram, computerized cardiac tomography, and others. By end user, it is classified into hospitals, diagnostics centers, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Competition Analysis

The major players operating in the global heart attack diagnostics market include Bionet Co., Ltd, TOSHIBA CORPORATION, Bio-Rad Laboratories Inc, Life Sign LLC, Schiller AG, Beckman Coulter,Inc., GE Healthcare, Hitachi Medical Systems, F. Hoffmann-La Roche Ltd., and Abbott Laboratories. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Historic market data

Key Market Segments

By Type

  • Electrocardiogram
  • Blood Tests
  • Angiogram
  • Computerized Cardiac Tomography
  • Others

By End User

  • Hospitals
  • Diagnostics Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • Bionet Co., Ltd
    • TOSHIBA CORPORATION
    • Bio-Rad Laboratories Inc
    • Life Sign LLC
    • Schiller AG
    • Beckman Coulter,Inc.
    • GE Healthcare
    • Hitachi Medical Systems
    • F. Hoffmann-La Roche Ltd.
    • Abbott Laboratories

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.5. Market Dynamics
    • 3.5.1. Drivers
    • 3.5.2. Restraints
    • 3.5.3. Opportunities

CHAPTER 4: HEART ATTACK DIAGNOSTICS MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. Electrocardiogram
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Blood Tests
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Angiogram
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Computerized Cardiac Tomography
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country
  • 4.6. Others
    • 4.6.1. Key Market Trends, Growth Factors and Opportunities
    • 4.6.2. Market Size and Forecast, By Region
    • 4.6.3. Market Share Analysis, By Country

CHAPTER 5: HEART ATTACK DIAGNOSTICS MARKET, BY END USER

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By End User
  • 5.2. Hospitals
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Diagnostics Centers
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Others
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: HEART ATTACK DIAGNOSTICS MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Type
    • 6.2.3. Market Size and Forecast, By End User
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Heart Attack Diagnostics Market
      • 6.2.5.1. Market Size and Forecast, By Type
      • 6.2.5.2. Market Size and Forecast, By End User
    • 6.2.6. Canada Heart Attack Diagnostics Market
      • 6.2.6.1. Market Size and Forecast, By Type
      • 6.2.6.2. Market Size and Forecast, By End User
    • 6.2.7. Mexico Heart Attack Diagnostics Market
      • 6.2.7.1. Market Size and Forecast, By Type
      • 6.2.7.2. Market Size and Forecast, By End User
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Type
    • 6.3.3. Market Size and Forecast, By End User
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. France Heart Attack Diagnostics Market
      • 6.3.5.1. Market Size and Forecast, By Type
      • 6.3.5.2. Market Size and Forecast, By End User
    • 6.3.6. Germany Heart Attack Diagnostics Market
      • 6.3.6.1. Market Size and Forecast, By Type
      • 6.3.6.2. Market Size and Forecast, By End User
    • 6.3.7. Italy Heart Attack Diagnostics Market
      • 6.3.7.1. Market Size and Forecast, By Type
      • 6.3.7.2. Market Size and Forecast, By End User
    • 6.3.8. Spain Heart Attack Diagnostics Market
      • 6.3.8.1. Market Size and Forecast, By Type
      • 6.3.8.2. Market Size and Forecast, By End User
    • 6.3.9. UK Heart Attack Diagnostics Market
      • 6.3.9.1. Market Size and Forecast, By Type
      • 6.3.9.2. Market Size and Forecast, By End User
    • 6.3.10. Rest of Europe Heart Attack Diagnostics Market
      • 6.3.10.1. Market Size and Forecast, By Type
      • 6.3.10.2. Market Size and Forecast, By End User
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Type
    • 6.4.3. Market Size and Forecast, By End User
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. China Heart Attack Diagnostics Market
      • 6.4.5.1. Market Size and Forecast, By Type
      • 6.4.5.2. Market Size and Forecast, By End User
    • 6.4.6. Japan Heart Attack Diagnostics Market
      • 6.4.6.1. Market Size and Forecast, By Type
      • 6.4.6.2. Market Size and Forecast, By End User
    • 6.4.7. India Heart Attack Diagnostics Market
      • 6.4.7.1. Market Size and Forecast, By Type
      • 6.4.7.2. Market Size and Forecast, By End User
    • 6.4.8. South Korea Heart Attack Diagnostics Market
      • 6.4.8.1. Market Size and Forecast, By Type
      • 6.4.8.2. Market Size and Forecast, By End User
    • 6.4.9. Australia Heart Attack Diagnostics Market
      • 6.4.9.1. Market Size and Forecast, By Type
      • 6.4.9.2. Market Size and Forecast, By End User
    • 6.4.10. Rest of Asia-Pacific Heart Attack Diagnostics Market
      • 6.4.10.1. Market Size and Forecast, By Type
      • 6.4.10.2. Market Size and Forecast, By End User
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Type
    • 6.5.3. Market Size and Forecast, By End User
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Heart Attack Diagnostics Market
      • 6.5.5.1. Market Size and Forecast, By Type
      • 6.5.5.2. Market Size and Forecast, By End User
    • 6.5.6. South Africa Heart Attack Diagnostics Market
      • 6.5.6.1. Market Size and Forecast, By Type
      • 6.5.6.2. Market Size and Forecast, By End User
    • 6.5.7. Saudi Arabia Heart Attack Diagnostics Market
      • 6.5.7.1. Market Size and Forecast, By Type
      • 6.5.7.2. Market Size and Forecast, By End User
    • 6.5.8. Rest of LAMEA Heart Attack Diagnostics Market
      • 6.5.8.1. Market Size and Forecast, By Type
      • 6.5.8.2. Market Size and Forecast, By End User

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. Bionet Co., Ltd
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. TOSHIBA CORPORATION
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Bio-Rad Laboratories Inc
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. Life Sign LLC
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Schiller AG
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. Beckman Coulter, Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. GE Healthcare
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Hitachi Medical Systems
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. F. Hoffmann-La Roche Ltd.
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. Abbott Laboratories
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Developments